Conditions: Osteoporosis
Keywords: postmenopausal women with primary osteoporosis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 82
Healthy volunteers: no

Brief summary:
The primary objective of this trial is to show that PTH(1-84) is superior to strontium ranelate in bone formation measured as changes in bone formation markers over a treatment period of 24 weeks in postmenopausal women with primary osteoporosis.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Full Length Parathyroid Hormone, PTH(1-84) intervention 2: Strontium Ranelate
Intervention descriptions: intervention 1: Once daily subcutaneous injection in the abdomen by self administration intervention 2: The daily dose of 2 g (one sachet) strontium ranelate was to be mixed in a glass of water and taken immediately after mixing at bedtime at least 2 hours before or after intake of calcium, any food or drinks, other than water

Protocol document: